Ally Bridge Group NY LLC Buys New Shares in Eupraxia Pharmaceuticals Inc. $EPRX

Ally Bridge Group NY LLC bought a new position in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 915,000 shares of the company’s stock, valued at approximately $5,398,000. Eupraxia Pharmaceuticals accounts for about 3.3% of Ally Bridge Group NY LLC’s holdings, making the stock its 10th largest holding. Ally Bridge Group NY LLC owned about 2.54% of Eupraxia Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada lifted its position in shares of Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after acquiring an additional 59,683 shares in the last quarter. UBS Group AG grew its position in shares of Eupraxia Pharmaceuticals by 155.4% during the third quarter. UBS Group AG now owns 95,756 shares of the company’s stock worth $565,000 after purchasing an additional 58,257 shares in the last quarter. Ingalls & Snyder LLC grew its position in shares of Eupraxia Pharmaceuticals by 58.9% during the third quarter. Ingalls & Snyder LLC now owns 59,100 shares of the company’s stock worth $349,000 after purchasing an additional 21,900 shares in the last quarter. Raymond James Financial Inc. raised its stake in Eupraxia Pharmaceuticals by 173.3% during the 3rd quarter. Raymond James Financial Inc. now owns 33,373 shares of the company’s stock valued at $197,000 after purchasing an additional 21,161 shares during the period. Finally, Guardian Partners Inc. purchased a new position in Eupraxia Pharmaceuticals in the 3rd quarter worth approximately $147,000.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Cantor Fitzgerald boosted their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Friday, January 9th. Finally, Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $15.50.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX opened at $7.36 on Friday. The company’s fifty day moving average is $8.29 and its 200 day moving average is $6.83. Eupraxia Pharmaceuticals Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $9.32. The stock has a market capitalization of $264.67 million, a PE ratio of -7.15 and a beta of 1.27.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.21). As a group, research analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.67 earnings per share for the current year.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.